Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor

Yusuke Katanuma, Tadahiro Numakawa, Naoki Adachi, Noriko Yamamoto, Yoshiko Ooshima, Odaka Haruki, Takafumi Inoue, Hiroshi Kunugi

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    Downregulation of brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, has been implicated in psychiatric diseases including schizophrenia. However, detailed mechanisms of its reduction in patients with schizophrenia remain unclear. Here, using cultured cortical neurons, we monitored BDNF mRNA levels following acute application of phencyclidine [PCP; an N-methyl-d-aspartate (NMDA) receptor blocker], which is known to produce schizophrenia-like symptoms. We found that PCP rapidly caused a reduction in total amount of BDNF transcripts without effect on cell viability, while mRNA levels of nerve growth factor was intact. Actinomycin-D (ActD), an RNA synthesis inhibitor, decreased total BDNF mRNA levels similar to PCP, and coapplication of ActD with PCP did not show further reduction in BDNF mRNA compared with solo application of each drug. Among BDNF exons I, IV, and VI, the exon IV, which is positively regulated by neuronal activity, was highly sensitive to PCP. Furthermore, PCP inactivated cAMP response element-binding protein (CREB; a regulator of transcriptional activity of exon IV). The inactivation of CREB was also achieved by an inhibitor for Ca2+/calmodulin kinase II (CaMKII), although coapplication with PCP induced no further inhibition on the CREB activity. It is possible that PCP decreases BDNF transcription via blocking the NMDA receptor/CaMKII/CREB signaling.

    Original languageEnglish
    Pages (from-to)257-265
    Number of pages9
    JournalSynapse
    Volume68
    Issue number6
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Phencyclidine
    Brain-Derived Neurotrophic Factor
    Messenger RNA
    Exons
    Schizophrenia
    Calcium-Calmodulin-Dependent Protein Kinases
    Dactinomycin
    Nucleic Acid Synthesis Inhibitors
    Cyclic AMP Response Element-Binding Protein
    Nerve Growth Factors
    Nerve Growth Factor
    Psychiatry
    Cell Survival
    Down-Regulation
    Neurons
    Pharmaceutical Preparations

    Keywords

    • BDNF
    • NMDA receptor
    • Phencyclidine
    • Schizophrenia

    ASJC Scopus subject areas

    • Cellular and Molecular Neuroscience
    • Medicine(all)

    Cite this

    Katanuma, Y., Numakawa, T., Adachi, N., Yamamoto, N., Ooshima, Y., Haruki, O., ... Kunugi, H. (2014). Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor. Synapse, 68(6), 257-265. https://doi.org/10.1002/syn.21735

    Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor. / Katanuma, Yusuke; Numakawa, Tadahiro; Adachi, Naoki; Yamamoto, Noriko; Ooshima, Yoshiko; Haruki, Odaka; Inoue, Takafumi; Kunugi, Hiroshi.

    In: Synapse, Vol. 68, No. 6, 2014, p. 257-265.

    Research output: Contribution to journalArticle

    Katanuma, Y, Numakawa, T, Adachi, N, Yamamoto, N, Ooshima, Y, Haruki, O, Inoue, T & Kunugi, H 2014, 'Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor', Synapse, vol. 68, no. 6, pp. 257-265. https://doi.org/10.1002/syn.21735
    Katanuma Y, Numakawa T, Adachi N, Yamamoto N, Ooshima Y, Haruki O et al. Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor. Synapse. 2014;68(6):257-265. https://doi.org/10.1002/syn.21735
    Katanuma, Yusuke ; Numakawa, Tadahiro ; Adachi, Naoki ; Yamamoto, Noriko ; Ooshima, Yoshiko ; Haruki, Odaka ; Inoue, Takafumi ; Kunugi, Hiroshi. / Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor. In: Synapse. 2014 ; Vol. 68, No. 6. pp. 257-265.
    @article{b1a81f21edde4984b5465581f6fc29a3,
    title = "Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor",
    abstract = "Downregulation of brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, has been implicated in psychiatric diseases including schizophrenia. However, detailed mechanisms of its reduction in patients with schizophrenia remain unclear. Here, using cultured cortical neurons, we monitored BDNF mRNA levels following acute application of phencyclidine [PCP; an N-methyl-d-aspartate (NMDA) receptor blocker], which is known to produce schizophrenia-like symptoms. We found that PCP rapidly caused a reduction in total amount of BDNF transcripts without effect on cell viability, while mRNA levels of nerve growth factor was intact. Actinomycin-D (ActD), an RNA synthesis inhibitor, decreased total BDNF mRNA levels similar to PCP, and coapplication of ActD with PCP did not show further reduction in BDNF mRNA compared with solo application of each drug. Among BDNF exons I, IV, and VI, the exon IV, which is positively regulated by neuronal activity, was highly sensitive to PCP. Furthermore, PCP inactivated cAMP response element-binding protein (CREB; a regulator of transcriptional activity of exon IV). The inactivation of CREB was also achieved by an inhibitor for Ca2+/calmodulin kinase II (CaMKII), although coapplication with PCP induced no further inhibition on the CREB activity. It is possible that PCP decreases BDNF transcription via blocking the NMDA receptor/CaMKII/CREB signaling.",
    keywords = "BDNF, NMDA receptor, Phencyclidine, Schizophrenia",
    author = "Yusuke Katanuma and Tadahiro Numakawa and Naoki Adachi and Noriko Yamamoto and Yoshiko Ooshima and Odaka Haruki and Takafumi Inoue and Hiroshi Kunugi",
    year = "2014",
    doi = "10.1002/syn.21735",
    language = "English",
    volume = "68",
    pages = "257--265",
    journal = "Synapse",
    issn = "0887-4476",
    publisher = "Wiley-Liss Inc.",
    number = "6",

    }

    TY - JOUR

    T1 - Phencyclidine rapidly decreases neuronal mRNA of brain-derived neurotrophic factor

    AU - Katanuma, Yusuke

    AU - Numakawa, Tadahiro

    AU - Adachi, Naoki

    AU - Yamamoto, Noriko

    AU - Ooshima, Yoshiko

    AU - Haruki, Odaka

    AU - Inoue, Takafumi

    AU - Kunugi, Hiroshi

    PY - 2014

    Y1 - 2014

    N2 - Downregulation of brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, has been implicated in psychiatric diseases including schizophrenia. However, detailed mechanisms of its reduction in patients with schizophrenia remain unclear. Here, using cultured cortical neurons, we monitored BDNF mRNA levels following acute application of phencyclidine [PCP; an N-methyl-d-aspartate (NMDA) receptor blocker], which is known to produce schizophrenia-like symptoms. We found that PCP rapidly caused a reduction in total amount of BDNF transcripts without effect on cell viability, while mRNA levels of nerve growth factor was intact. Actinomycin-D (ActD), an RNA synthesis inhibitor, decreased total BDNF mRNA levels similar to PCP, and coapplication of ActD with PCP did not show further reduction in BDNF mRNA compared with solo application of each drug. Among BDNF exons I, IV, and VI, the exon IV, which is positively regulated by neuronal activity, was highly sensitive to PCP. Furthermore, PCP inactivated cAMP response element-binding protein (CREB; a regulator of transcriptional activity of exon IV). The inactivation of CREB was also achieved by an inhibitor for Ca2+/calmodulin kinase II (CaMKII), although coapplication with PCP induced no further inhibition on the CREB activity. It is possible that PCP decreases BDNF transcription via blocking the NMDA receptor/CaMKII/CREB signaling.

    AB - Downregulation of brain-derived neurotrophic factor (BDNF), a member of neurotrophin family, has been implicated in psychiatric diseases including schizophrenia. However, detailed mechanisms of its reduction in patients with schizophrenia remain unclear. Here, using cultured cortical neurons, we monitored BDNF mRNA levels following acute application of phencyclidine [PCP; an N-methyl-d-aspartate (NMDA) receptor blocker], which is known to produce schizophrenia-like symptoms. We found that PCP rapidly caused a reduction in total amount of BDNF transcripts without effect on cell viability, while mRNA levels of nerve growth factor was intact. Actinomycin-D (ActD), an RNA synthesis inhibitor, decreased total BDNF mRNA levels similar to PCP, and coapplication of ActD with PCP did not show further reduction in BDNF mRNA compared with solo application of each drug. Among BDNF exons I, IV, and VI, the exon IV, which is positively regulated by neuronal activity, was highly sensitive to PCP. Furthermore, PCP inactivated cAMP response element-binding protein (CREB; a regulator of transcriptional activity of exon IV). The inactivation of CREB was also achieved by an inhibitor for Ca2+/calmodulin kinase II (CaMKII), although coapplication with PCP induced no further inhibition on the CREB activity. It is possible that PCP decreases BDNF transcription via blocking the NMDA receptor/CaMKII/CREB signaling.

    KW - BDNF

    KW - NMDA receptor

    KW - Phencyclidine

    KW - Schizophrenia

    UR - http://www.scopus.com/inward/record.url?scp=84897544807&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84897544807&partnerID=8YFLogxK

    U2 - 10.1002/syn.21735

    DO - 10.1002/syn.21735

    M3 - Article

    VL - 68

    SP - 257

    EP - 265

    JO - Synapse

    JF - Synapse

    SN - 0887-4476

    IS - 6

    ER -